Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPHA President Jaeger Keynotes Lehman Investment Conference March 31

This article was originally published in The Pink Sheet Daily

Executive Summary

GPHA priorities of follow-on biologics, “authorized” generics are likely to be highlighted. CMS’ Trysla gives opening address at March 30-April 1 investment conference in Miami Beach.

You may also be interested in...



GPhA's 2005 Priorities Include Generic Biologics, Biodefense Incentives

The Generic Pharmaceutical Association will continue to push for an approval pathway for generic biologics and work against "authorized" generics and patent term exclusivity extensions contained in biodefense legislation, President Jaeger tells group's annual meeting.

Editor's Note: Please Help Pink Sheet Serve You Best

Please take our brief reader survey to help us better understand your content and delivery needs.

Editor’s Choice: Notable Pink Sheet Articles From Q3

A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel